Amel Ben Saad

Ms. Amel Ben Saad

Inserm 1193
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2023 in The EMBO Journal
Verified
Journal Article
Open access
AHAnja Hess
Anja Hess
SGStefan D Gentile
Stefan D Gentile
ASAmel Ben Saad
Amel Ben Saad
RRRaza‐Ur Rahman
Raza‐Ur Rahman
THTim Habboub
Tim Habboub
AMAlan C Mullen
Alan C Mullen
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a growing cause of morbidity with limited treatment options. Thus, accurate in vitro systems to test new therapies are indispensable. While recently, human liver organoid models have emerged to assess steatotic liver disease, a systematic evaluation of their translational potential is still missing. Here, we evaluated human liver organoid models of MASLD, comparatively testing disease induction in three conditions: oleic acid, palmitic acid, and TGF‐β1. Through single‐cell analyses, we find that all three models induce inflammatory signatures, but only TGF‐β1 promotes collagen production, fibrosis, and hepatic stellate cell expansion. In striking contrast, oleic acid ameliorates fibrotic signatures and reduces the hepatic stellate cell population. Linking data from each model to gene expression signatures associated with MASLD disease progression further demonstrates that palmitic acid and TGF‐β1 more robustly model inflammation and fibrosis. Our findings highlight the importance of stratifying MASLD organoid models by signatures of clinical disease progression, provide a single‐cell reference to benchmark future organoid injury models, and allow us to study evolving steatohepatitis, fibrosis, and HSC susceptibility to injury in a dynamic, multi‐lineage human in vitro system.

Verified
Journal Article
Open access
PDF file
ASAmel Ben Saad
Amel Ben Saad
BBBruneau Bruneau
Bruneau Bruneau
Elodie MareuxElodie Mareux
Elodie Mareux
MLMartine LAPALUS
Martine LAPALUS
jean-louis Delaunayjean-louis Delaunay
jean-louis Delaunay
Thomas FalguièresThomas Falguières
Thomas Falguières
The ATP-binding cassette (ABC) transporters expressed at the canalicular membrane of hepatocytes mediate the secretion of several compounds into the bile canaliculi and therefore play a key role in bile secretion. Among these transporters, ABCB11 secretes bile acids, ABCB4 translocates phosphatidylcholine and ABCG5/G8 is responsible for cholesterol secretion, while ABCB1 and ABCC2 transport a variety of drugs and other compounds. The dysfunction of these transporters leads to severe, rare, evolutionary biliary diseases. The development of new therapies for patients with these diseases requires a deep understanding of the biology of these transporters. In this review, we report the current knowledge regarding the regulation of canalicular ABC transporters’ folding, trafficking, membrane stability and function, and we highlight the role of molecular partners in these regulating mechanisms.

30 April 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VVVirginie Vauthier
Virginie Vauthier
ASAmel Ben Saad
Amel Ben Saad
JEJonathan Elie
Jonathan Elie
NONassima Oumata
Nassima Oumata
ADAnne-Marie Durand-Schneider
Anne-Marie Durand-Schneider
Thomas FalguièresThomas Falguières
Thomas Falguières
Adenosine triphosphate binding cassette transporter, subfamily B member 4 (ABCB4) is the transporter of phosphatidylcholine at the canalicular membrane of hepatocytes. ABCB4 deficiency, due to genetic variations, is responsible for progressive familial intrahepatic cholestasis type 3 (PFIC3) and other rare biliary diseases. Roscovitine is a molecule in clinical trial that was shown to correct the F508del variant of cystic fibrosis transmembrane conductance regulator (CFTR), another ABC transporter. In the present study, we hypothesized that roscovitine could act as a corrector of ABCB4 traffic-defective variants. Using HEK and HepG2 cells, we showed that roscovitine corrected the traffic and localisation at the plasma membrane of ABCB4-I541F, a prototypical intracellularly retained variant. However, roscovitine caused cytotoxicity, which urged us to synthesize non-toxic structural analogues. Roscovitine analogues were able to correct the intracellular traffic of ABCB4-I541F in HepG2 cells. Importantly, the phospholipid secretion activity of this variant was substantially rescued by three analogues (MRT2-235, MRT2-237 and MRT2-243) in HEK cells. We showed that these analogues also triggered the rescue of intracellular traffic and function of two other intracellularly retained ABCB4 variants, i.e. I490T and L556R. Our results indicate that structural analogues of roscovitine can rescue genetic variations altering the intracellular traffic of ABCB4 and should be considered as therapeutic means for severe biliary diseases caused by this class of variations.

1 March 2021 in Liver International
Verified
Journal Article
Closed access
PDF file
ASAmel Ben Saad
Amel Ben Saad
VVVirginie Vauthier
Virginie Vauthier
ÁTÁgota Tóth
Ágota Tóth
AJAngelika Janaszkiewicz
Angelika Janaszkiewicz
ADAnne‐Marie Durand‐Schneider
Anne‐Marie Durand‐Schneider
Thomas FalguièresThomas Falguières
Thomas Falguières

18 November 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
EMElodie Mareux
Elodie Mareux
MLMartine Lapalus
Martine Lapalus
ASAmel Ben Saad
Amel Ben Saad
ICIsabelle Callebaut
Isabelle Callebaut
TFThomas Falguières
Thomas Falguières
EJEmmanuel Jacquemin
Emmanuel Jacquemin
Background: ABCB11 variations are responsible for a spectrum of rare liver diseases, including progressive familial intrahepatic cholestasis type 2 (PFIC2) and intrahepatic cholestasis of pregnancy (ICP). Current medical treatment of these conditions mostly relies on ursodeoxycholic acid with limited efficacy. We report on the in vitro study of the p.A257V missense variant of ABCB11 identified in a PFIC2 patient and in her mother who experienced ICP. Results: The Ala257 residue is located outside the ATP-binding site of ABCB11. We show that the p.A257V variant of ABCB11 is correctly expressed at the canalicular membrane of HepG2 cells but that its function significantly decreased when studied in MDCK cells. This functional defect can be fully rescued by Ivacaftor. Conclusion: Ivacaftor could be considered as a new pharmacological tool able to respond to an unmet medical need for patients with ICP and PFIC2 due to ABCB11 variations affecting ABCB11 function, even when the residue involved is not located in an ATP-binding site of ABCB11.

Verified
Journal Article
Open access
PDF file
ASAmel Ben Saad
Amel Ben Saad
VVVirginie Vauthier
Virginie Vauthier
MLMartine LAPALUS
Martine LAPALUS
Elodie MareuxElodie Mareux
Elodie Mareux
EBEvangéline Bennana
Evangéline Bennana
Thomas FalguièresThomas Falguières
Thomas Falguières
ABCB4 (ATP-binding cassette subfamily B member 4) is an ABC transporter expressed at the canalicular membrane of hepatocytes where it ensures phosphatidylcholine secretion into bile. Genetic variations of ABCB4 are associated with several rare cholestatic diseases. The available treatments are not efficient for a significant proportion of patients with ABCB4-related diseases and liver transplantation is often required. The development of novel therapies requires a deep understanding of the molecular mechanisms regulating ABCB4 expression, intracellular traffic, and function. Using an immunoprecipitation approach combined with mass spectrometry analyses, we have identified the small GTPase RAB10 as a novel molecular partner of ABCB4. Our results indicate that the overexpression of wild type RAB10 or its dominant-active mutant significantly increases the amount of ABCB4 at the plasma membrane expression and its phosphatidylcholine floppase function. Contrariwise, RAB10 silencing induces the intracellular retention of ABCB4 and then indirectly diminishes its secretory function. Taken together, our findings suggest that RAB10 regulates the plasma membrane targeting of ABCB4 and consequently its capacity to mediate phosphatidylcholine secretion.